Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 3283142 Phase 1 in Healthy Japanese Males
NCT05800444Phase 1Completed
- Sponsor
- Bayer
- Start
- Apr 2023
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of BAY3283142 in chronic kidney disease (CKD) (4 arms), sponsored by Bayer. Primary endpoint: Treatment-Emergent Adverse Events. Started Apr 2023; status: completed.
02
Drugs
BAY3283142
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT05800444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05800444.